Antigen-Presenting Cell Assay for Transplant Rejection Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and predicting transplant rejection, such as acute cellular rejection and humoral rejection, are not highly sensitive or specific, leading to a need for a more effective assay to monitor antigen uptake and presentation by antigen-presenting cells (APCs) to predict organ transplant rejection and graft-versus-host disease.
Innovation Solution
Developing methods and assays to measure antigen-presenting function, including contacting APCs from a subject with donor or recipient antigens to assess the antigen presenting index (API), which compares the uptake of donor antigens to third-party antigens, indicating the risk of rejection or graft-versus-host disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional methods (PRA testing) are used to predict transplant rejection, then the diagnostic process is simple and widely available, but the sensitivity and specificity are low leading to inaccurate predictions
Solution Approach 1:
The assay segments the prediction process into distinct functional measurements: antigen uptake by APCs, antigen presentation to T cells, and differentiation outcomes. This segmentation allows each component to be measured and optimized independently, achieving high prediction accuracy through cumulative functional assessment rather than relying on a single complex marker.
Solution Approach 2:
The patent uses antigen-presenting cells (APCs) as intermediaries to bridge the donor antigens and recipient T cells. This intermediary system naturally performs the complex immunological processing and presentation functions, converting complex immune interactions into measurable functional outcomes without requiring direct measurement of multiple individual immune parameters.
2Ease of operation
If PRA levels are measured to assess rejection risk, then the test is easy to perform, but the results are not highly sensitive or specific for predicting acute cellular or humoral rejection
Solution Approach 1:
The assay changes the measured parameters from static antibody levels (PRA) to dynamic functional parameters including antigen uptake rate, antigen presentation efficiency, and T cell differentiation responses. These functional parameters provide more reliable prediction of rejection outcomes while maintaining operational feasibility through standardized in vitro protocols.
3Measurement precision
If a highly sensitive and specific assay is developed to predict transplant rejection, then prediction accuracy improves to at least 90%, but the assay complexity increases requiring measurement of multiple functional parameters
Solution Approach 1:
The assay uses a universal platform where antigen-presenting cells perform multiple functions sequentially: uptake of labeled donor antigens, presentation to recipient T cells, and induction of differentiation. This multi-functionality is achieved within a single integrated system, allowing high prediction accuracy without requiring separate complex assays for each functional parameter.
Solution Approach 2:
The patent replaces complex mechanical measurement systems with biological functional assays. Instead of measuring multiple individual immune parameters through separate mechanical or chemical methods, the system uses living cells to perform the measurements biologically, reading out functional outcomes that inherently integrate multiple parameters into comprehensible rejection risk predictions.
Data Source
AI summary
Disclosed herein are methods for diagnosing or predicting acute cellular and/or humoral rejection in a subject. In one example, a method of assessing organ rejection includes contacting a first sample comprising antigen presenting cells (APCs) obtained from a subject in need of or having received an organ transplant with a donor antigen from a donor under conditions sufficient to induce uptake of the donor antigen; contacting a second sample comprising APCs obtained from the subject in need of or having received an organ transplant with a third-party antigen under conditions sufficient to induce uptake of the third-party antigen; and determining an antigen presenting index by determining a ratio of uptake of the donor antigen in the first sample to uptake of the third-party antigen in the second sample, wherein the ratio of greater than one indicates organ rejection and the APCs are monocytes or monocyte-derived cells.